Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer immunotherapy with levamisole.

H Miwa, K Orita

    Acta Medica Okayama
    |July 1, 1978
    PubMed
    Summary

    Levamisole therapy improved survival rates in gastrointestinal cancer patients, particularly those with non-resectable tumors. This immunomodulating agent demonstrated significant benefits in both six-month and one-year survival outcomes compared to control groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of <i>TP53</i> status in gemcitabine plus nab-paclitaxel therapy.

    ESMO gastrointestinal oncology·2026
    Same author

    Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings.

    ESMO open·2025
    Same author

    Histomorphological changes in the ileal mucosa in secondary amyloidosis.

    QJM : monthly journal of the Association of Physicians·2021
    Same author

    Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments.

    Science advances·2020
    Same author

    Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation.

    Neurogastroenterology and motility·2018
    Same author

    Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study).

    Neurogastroenterology and motility·2018

    Area of Science:

    • Immunology
    • Oncology
    • Gastroenterology

    Background:

    • Levamisole is an immunomodulating agent known to enhance cellular immunity.
    • Impaired cellular immunity is often observed in cancer patients.
    • Levamisole has demonstrated potential antitumor activity.

    Purpose of the Study:

    • To evaluate the efficacy of levamisole in improving survival rates for patients with gastrointestinal cancer.
    • To assess the impact of levamisole on survival across different surgical resection statuses (curative, noncurative, non-resectable).

    Main Methods:

    • A study involving 143 gastrointestinal cancer patients treated with levamisole (150 mg daily for three days every other week, initiated pre-operatively).
    • A control group of 185 gastrointestinal cancer patients for comparison.
    • Survival rates (six-month and one-year) were evaluated based on surgical resection status.

    Main Results:

    • Levamisole treatment showed a trend towards improved six-month survival after curative resection (100% vs 95.3%) and significant improvement after noncurative resection (100% vs 90.5%) and in non-resectable cases (72.5% vs 33.3%).
    • One-year survival rates also favored the levamisole group, with notable differences in noncurative (77.8% vs 59.3%) and non-resectable patients (40% vs 8.3%).
    • The most pronounced survival benefit of levamisole was observed in patients with non-resectable gastrointestinal cancer.

    Conclusions:

    • Levamisole therapy demonstrates a significant survival benefit for patients with gastrointestinal cancer, especially in advanced or non-resectable stages.
    • The immunomodulatory effects of levamisole may contribute to its antitumor activity and improved patient outcomes.
    • Further research into levamisole as an adjuvant therapy for gastrointestinal cancers is warranted.

    Related Experiment Videos